Evogene Ltd. (EVGN) Financials

EVGN Assets vs Liabilities
DateAssetsLiabilities
March 31, 2026 17.9 million 6.8 million
Dec. 31, 2025 20.0 million 5.0 million
Sept. 30, 2025 26.1 million 6.0 million
June 30, 2025 33.9 million 21.6 million

EVGN Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
March 31, 2026 -3.0 million ?
Dec. 31, 2025 -3.0 million 155000
Sept. 30, 2025 -3.8 million 27000
June 30, 2025 -2.3 million 234000

EVGN Net Income

No data available :(

EVGN Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
March 31, 2026 13.1 million - 1.4 million
Dec. 31, 2025 13.0 million - 2.2 million
Sept. 30, 2025 16.0 million - 2.5 million
June 30, 2025 11.7 million - 2.7 million

EVGN Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
March 31, 2026 9.7 million
Dec. 31, 2025 8.7 million
Sept. 30, 2025 8.7 million
June 30, 2025 7.2 million

EVGN Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
March 31, 2026 2000 8.0 million 5.8 million 1.5 million
Dec. 31, 2025 8295 1.8 million 1.2 million -993000
Sept. 30, 2025 11292 1.4 million 1.5 million 369000
June 30, 2025 2000 2.3 million 1.5 million 412000

EVGN Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
March 31, 2026 3.9 million 4.1 million
Dec. 31, 2025 314000 2.3 million
Sept. 30, 2025 312000 157000
June 30, 2025 884000 136000

EVGN

Price: $0.52

52 week price:
0.37
1.50

Earnings Per Share: -1.70 USD

Exchange: NCM

Sector: Healthcare

Industry: Biotechnology

Country: Israel

Volume: 71621

Ebitda: -8.5 million

Market Capitalization: 3.7 million

Links: